Nov 7 (Reuters) - Three members of the U.S. Senate Judiciary
Committee, ahead of a planned hearing late this month, said
Mylan NV appears to have greatly overcharged the
military for its lifesaving allergy treatment EpiPen and asked
the pharmaceutical company when it plans to reimburse the
Department of Defense.
Read more
No comments:
Post a Comment